Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Shelter Pharma Limited, originally Shelter Pharmacy, is a manufacturer of ayurvedic and herbal products with a strong presence in the Human and Veterinary Pharma sectors.
Originally a local business in Himmatnagar, it expanded throughout Gujarat, leveraging in-house R&D for product portfolio enhancement.
Recently, Shelter Pharma underwent organizational restructuring, invested in manufacturing capacity, and sourced raw materials directly from nearby farmers.
Its recent IPO raised approximately Rs 16.02 Crore, indicating robust investor confidence for expansion plans.
The company is continuing its expansion strategically, leveraging a strong product portfolio and focused marketing to capture opportunities in both human and veterinary markets.
Pharmaceuticals & Biotechnology
Pharmaceuticals
47 Cr
High Risk
5.2
34.6
0.1
0.7
50.00
26.50
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Shelter Pharma Ltd (SHELTER) is currently trading at 28.02 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Shelter Pharma Limited, originally Shelter Pharmacy, is a manufacturer of ayurvedic and herbal products with a strong presence in the Human and Veterinary Pharma sectors. Originally a local business in Himmatnagar, it expanded throughout Gujarat, leveraging in-house R&D for product portfolio enhancement. Recently, Shelter Pharma underwent organizational restructuring, invested in manufacturing capacity, and sourced raw materials directly from nearby farmers. Its recent IPO raised approximately Rs 16.02 Crore, indicating robust investor confidence for expansion plans. The company is continuing its expansion strategically, leveraging a strong product portfolio and focused marketing to capture opportunities in both human and veterinary markets.
Over the past 52 weeks, Shelter Pharma Ltd has traded between a low of ₹26.50 and a high of ₹50.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Shelter Pharma Ltd has a market capitalization of approximately 47.18. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Shelter Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 5.22 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 47.18 Cr, Shelter Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Shelter Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Shelter Pharma Ltd is 5.22. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Investor Presentation
Q4 FY26
Bearish
3
Neutral
3
Bullish
8
Bearish
35
Neutral
3
Bullish
8
Bearish
32
Neutral
0
Bullish
0
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
5.90 | 49 Cr | -1.41 | 0.00 | 0.00 | 50.81 | -2.49 | -3.78 | ||
30.19 | 48 Cr | -1.07 | 0.50 | 0.00 | -43.08 | -15.40 | -14.10 | ||
28.02 | 47 Cr | 5.22 | 0.65 | 0.00 | 11.78 | 15.93 | 10.72 | ||
7.41 | 46 Cr | -3.78 | 1.25 | 0.00 | -33.10 | -32.42 | -21.90 | ||
0.44 | 45 Cr | -8.38 | 0.44 | 0.00 | -6.13 | -7.99 | -4.91 | ||
42.77 | 41 Cr | 26.49 | 1.24 | 1.87 | 3.69 | 5.32 | 2.80 | ||
| Median: 6 Co. | — | 17.71 | 46 Cr | -1.24 | 0.57 | 0.00 | -1.22 | -5.24 | -4.35 |
Investor Conference Call
Shelter Pharma submitted the video recording of its investor conference call held on 19 June 2026 discussing the audited H2 FY26 and FY2026 financial results, filed under Regulation 30 to BSE.
Earnings presentation
Shelter Pharma submitted an investor presentation related to the audited financial results for the half year and year ended 31 Mar 2026 and made it available ahead of an investor conference call to discuss performance.
Investor Presentation
Shelter Pharma submitted an investor presentation related to the audited financial results for H2 and FY2026 (period ended 31 Mar 2026) and made it available ahead of an investor conference call (dated 17 Jun 2026).
Investor Conference Call
Shelter Pharma will host an investor conference call on 19 June 2026 at 4:00 PM IST to discuss the audited financial results for H2 & FY2026 and provide business and operational updates.
Investor Conference Call
Shelter Pharma will host an investor conference call on 19 June 2026 at 16:00 IST to discuss the audited H2 and FY2026 financial results and provide business/operational updates.
